雌激素受体与免疫检查点抑制剂：肺癌治疗的新伙伴？
Estrogen Receptor and Immune Checkpoint Inhibitors: New Partners in Lung Cancer?
机构信息
Program in Solid Tumors, CIMA-University of Navarra, Pamplona, Spain.
Consorcio de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
出版信息
Clin Cancer Res. 2023 Oct 2;29(19):3832-3834. doi: 10.1158/1078-0432.CCR-23-1736.
The influence of sex on immunotherapy response in patients with non-small cell lung cancer (NSCLC) had been studied with no clear conclusions. An article in this issue reports that a key determinant of response is not sex but the existence of a 17β-estradiol/ERα/PDL1 signaling loop in NSCLC. This intriguing result opens new therapeutic options. See related article by Anobile et al., p. 3958.
关于性别的因素对非小细胞肺癌（NSCLC）患者免疫治疗反应的影响已经进行了研究，但尚未得出明确结论。本期的一篇文章报道称，反应的一个关键决定因素不是性别，而是 NSCLC 中存在 17β-雌二醇/ERα/PDL1 信号通路。这一有趣的结果为治疗提供了新的选择。见 Anobile 等人的相关文章，第 3958 页。
Zotero 插件